20Nov 2022
In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

The neutralizing activity of plasma obtained from patients who recovered from Covid-19 and from recipient vaccines was lower against BA.4.6, BA.2, and BA.5 than it was against the ancestral strain. Furthermore, this reduction in neutralizing titers was larger for BA.4.6 and BA.5 than for BA.2. The data suggest that remdesivir, molnupiravir, and nirmatrelvir and the monoclonal antibodies bebtelovimab and imdevimab retain effectiveness against BA.4.6 in vitro. The findings also indicate that monoclonal antibodies casirivimab, sotrovimab, tixagevimab, and cilgavimab may not be effective against BA.4.6.

  • #family health

Like

Save

Share